AtriCure Net Income
| ATRC Stock | USD 36.80 1.27 3.34% |
As of the 5th of February, AtriCure shows the Risk Adjusted Performance of 0.0456, downside deviation of 3.1, and Mean Deviation of 2.36. AtriCure technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
AtriCure Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.5145 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -40.2 M | -38.2 M | |
| Net Loss | -40.2 M | -38.2 M | |
| Net Loss | -41.8 M | -39.7 M | |
| Net Loss | (0.86) | (0.90) | |
| Net Income Per E B T | 1.18 | 1.11 |
AtriCure | Net Income | Build AI portfolio with AtriCure Stock |
Analyzing AtriCure's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing AtriCure's current valuation and future prospects.
Latest AtriCure's Net Income Growth Pattern
Below is the plot of the Net Income of AtriCure over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in AtriCure financial statement analysis. It represents the amount of money remaining after all of AtriCure operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is AtriCure's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AtriCure's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (44.7 M) | 10 Years Trend |
|
Net Income |
| Timeline |
AtriCure Net Income Regression Statistics
| Arithmetic Mean | (22,707,911) | |
| Geometric Mean | 22,749,576 | |
| Coefficient Of Variation | (104.38) | |
| Mean Deviation | 16,912,809 | |
| Median | (27,212,000) | |
| Standard Deviation | 23,702,880 | |
| Sample Variance | 561.8T | |
| Range | 98.4M | |
| R-Value | (0.40) | |
| Mean Square Error | 503.7T | |
| R-Squared | 0.16 | |
| Significance | 0.11 | |
| Slope | (1,874,907) | |
| Total Sum of Squares | 8989.2T |
AtriCure Net Income History
Other Fundumenentals of AtriCure
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
AtriCure Net Income component correlations
AtriCure Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for AtriCure is extremely important. It helps to project a fair market value of AtriCure Stock properly, considering its historical fundamentals such as Net Income. Since AtriCure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AtriCure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AtriCure's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could AtriCure diversify its offerings? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AtriCure data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth 0.158 | Return On Assets | Return On Equity |
Understanding AtriCure requires distinguishing between market price and book value, where the latter reflects AtriCure's accounting equity. The concept of intrinsic value - what AtriCure's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push AtriCure's price substantially above or below its fundamental value.
Understanding that AtriCure's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AtriCure represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, AtriCure's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
AtriCure 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to AtriCure's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of AtriCure.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in AtriCure on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding AtriCure or generate 0.0% return on investment in AtriCure over 90 days. AtriCure is related to or competes with Quidel, BioLife Solutions, Kestra Medical, Azenta, 10X Genomics, Novocure, and Xeris Pharmaceuticals. AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and in... More
AtriCure Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure AtriCure's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess AtriCure upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.1 | |||
| Information Ratio | 0.0317 | |||
| Maximum Drawdown | 18.0 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 4.34 |
AtriCure Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for AtriCure's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as AtriCure's standard deviation. In reality, there are many statistical measures that can use AtriCure historical prices to predict the future AtriCure's volatility.| Risk Adjusted Performance | 0.0456 | |||
| Jensen Alpha | 0.0783 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0334 | |||
| Treynor Ratio | 0.1081 |
AtriCure February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0456 | |||
| Market Risk Adjusted Performance | 0.1181 | |||
| Mean Deviation | 2.36 | |||
| Semi Deviation | 2.88 | |||
| Downside Deviation | 3.1 | |||
| Coefficient Of Variation | 1943.37 | |||
| Standard Deviation | 3.26 | |||
| Variance | 10.66 | |||
| Information Ratio | 0.0317 | |||
| Jensen Alpha | 0.0783 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0334 | |||
| Treynor Ratio | 0.1081 | |||
| Maximum Drawdown | 18.0 | |||
| Value At Risk | (4.08) | |||
| Potential Upside | 4.34 | |||
| Downside Variance | 9.61 | |||
| Semi Variance | 8.3 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 0.4512 | |||
| Kurtosis | 2.26 |
AtriCure Backtested Returns
AtriCure appears to be very steady, given 3 months investment horizon. AtriCure secures Sharpe Ratio (or Efficiency) of 0.0852, which signifies that the company had a 0.0852 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for AtriCure, which you can use to evaluate the volatility of the firm. Please makes use of AtriCure's Mean Deviation of 2.36, risk adjusted performance of 0.0456, and Downside Deviation of 3.1 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, AtriCure holds a performance score of 6. The firm shows a Beta (market volatility) of 1.46, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AtriCure will likely underperform. Please check AtriCure's downside variance, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether AtriCure's price patterns will revert.
Auto-correlation | -0.57 |
Good reverse predictability
AtriCure has good reverse predictability. Overlapping area represents the amount of predictability between AtriCure time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of AtriCure price movement. The serial correlation of -0.57 indicates that roughly 57.0% of current AtriCure price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.57 | |
| Spearman Rank Test | -0.68 | |
| Residual Average | 0.0 | |
| Price Variance | 2.94 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
AtriCure Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, AtriCure reported net income of (44.7 Million). This is 113.1% lower than that of the Health Care Equipment & Supplies sector and 144.86% lower than that of the Health Care industry. The net income for all United States stocks is 107.83% higher than that of the company.
AtriCure Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AtriCure's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AtriCure could also be used in its relative valuation, which is a method of valuing AtriCure by comparing valuation metrics of similar companies.AtriCure is currently under evaluation in net income category among its peers.
AtriCure ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AtriCure's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AtriCure's managers, analysts, and investors.Environmental | Governance | Social |
AtriCure Institutional Holders
Institutional Holdings refers to the ownership stake in AtriCure that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of AtriCure's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AtriCure's value.| Shares | First Light Asset Management, Llc | 2025-06-30 | 1 M | Gw&k Investment Management, Llc | 2025-06-30 | 1 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 1 M | Nuveen, Llc | 2025-06-30 | 938.2 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 820.1 K | Bnp Paribas Investment Partners Sa | 2025-06-30 | 755.5 K | Goldman Sachs Group Inc | 1225-06-30 | 745 K | Ing Investment Management Llc | 2025-06-30 | 710.4 K | Bank Of America Corp | 2025-06-30 | 710.2 K | Vanguard Group Inc | 2025-06-30 | 4.9 M | Blackrock Inc | 2025-06-30 | 4 M |
AtriCure Fundamentals
| Return On Equity | -0.0611 | ||||
| Return On Asset | -0.0265 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 1.76 B | ||||
| Shares Outstanding | 49.72 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.81 % | ||||
| Number Of Shares Shorted | 2.51 M | ||||
| Price To Earning | 33.47 X | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 3.53 X | ||||
| Revenue | 465.31 M | ||||
| Gross Profit | 388.06 M | ||||
| EBITDA | (18.53 M) | ||||
| Net Income | (44.7 M) | ||||
| Cash And Equivalents | 118.45 M | ||||
| Cash Per Share | 2.55 X | ||||
| Total Debt | 76.53 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.66 X | ||||
| Book Value Per Share | 9.59 X | ||||
| Cash Flow From Operations | 12.2 M | ||||
| Short Ratio | 5.39 X | ||||
| Earnings Per Share | (0.59) X | ||||
| Price To Earnings To Growth | (1.18) X | ||||
| Target Price | 52.78 | ||||
| Number Of Employees | 1.3 K | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 1.83 B | ||||
| Total Asset | 609.33 M | ||||
| Retained Earnings | (401.75 M) | ||||
| Working Capital | 194.4 M | ||||
| Current Asset | 74.75 M | ||||
| Current Liabilities | 31.59 M | ||||
| Net Asset | 609.33 M |
About AtriCure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AtriCure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AtriCure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AtriCure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock:Check out For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Will Health Care Equipment & Supplies sector continue expanding? Could AtriCure diversify its offerings? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AtriCure data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth 0.158 | Return On Assets | Return On Equity |
Understanding AtriCure requires distinguishing between market price and book value, where the latter reflects AtriCure's accounting equity. The concept of intrinsic value - what AtriCure's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push AtriCure's price substantially above or below its fundamental value.
Understanding that AtriCure's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AtriCure represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, AtriCure's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.